Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis

Obstructive sleep apnoea (OSA) is characterized by frequent apnoea episodes during sleep due to upper airway obstruction. The present review summarizes current knowledge on inter-relationships between OSA and type 2 diabetes mellitus (T2DM) and suggests the former as a possible target for sodium-glucose co-transporter-2 inhibitors (SGLT-2i). Based on pathophysiological mechanisms underlying OSA onset and renal SGLT-2 effects, we suggest that SGLT-2i indications might expand beyond current ones, including glucose, lipids, uric acid, blood pressure, and body weight control as well as chronic heart failure and kidney disease prevention.

Automated summary

This review examines the relationship between obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM), suggesting the potential use of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) as a treatment target. It also proposes that SGLT-2i indications could expand beyond current ones, including glucose, lipids, uric acid, blood pressure, and body weight control, as well as chronic heart failure and kidney disease prevention.